Table 3.

Summary of oncology clinical trials identified within the NIH database that selectively targeted CSNK2.

Cancer type	Study type	Population cohort	Intervention	Results	Reference
Cholangiocarcinoma	Phase I/II Clinical Trial	Unresectable or metastatic cholangiocarcinoma	Assessment of maximum tolerated dose CX4945, then administered with standard of care gemcitabine + cisplatin	Anticipated study completion August 2021.	NCT02128282
Multiple myeloma	Phase I Clinical Trial	Relapsed or refractory MM after at least 2 lines of therapy	CX4945 QID—dose escalation study	Study completed September 2011.	NCT01199718
Cervical	Phase II Clinical Trial	Local application of CIGB-300 to cervical adenocarcinoma or SCC	CIGB-300 15 mg, 35 mg, 75 mg locally applied	Study completed August 2016.	NCT01639625
Multiple sites	Phase I Clinical Trial	Dose escalation study for breast cancer, multiple myeloma, Castleman’s, advanced solid tumours	CX4945 BID or QID—dose escalation study	Study not completed.	NCT00891280

Cancer type, study phase, population, intervention, results and NCT number of the studies were listed. No oncology clinical trials targeting CSNK2 were identified in the EU Clinical Trials Register, Cancer Research UK Registry or Canadian Clinical Trials databases.